Ассоциация полиморфизмов H19 с риском развития рака молочной железы: мета-анализ

   Мета-анализ был направлен на оценку связи между полиморфизмами rs2107425, rs2839698, rs217727, rs3741219 гена H19 и риском развития рака молочной железы. Поиск публикаций проводили в базах данных Google Scholar и PubMed за последние 13 лет. Ассоциацию оценивали по статистическим критериям отношения шансов (ОШ) с 95 % доверительным интервалом (ДИ). Для проведения мета-анализа использовали программное обеспечение RevMan (Cochrane Collaboration, 5.3. Копенгаген). Для оценки связи четырех полиморфизмов rs2107425, rs2839698, rs217727, rs3741219 с риском развития рака молочной железы в мета-анализ были включены 9 исследований случай-контроль с общей выборкой из 6572 пациентов с раком молочной железы и 6968 доноров в контрольной группе. В результате исследования мы наблюдали связь между rs2839698 H19 и риском развития рака молочной железы в аллельной модели (ОШ = 1,33, 95 % ДИ: 1,00- 1,76, Pz = 0,005, Pi2 = <0.00001). Кроме того, в рецессивной модели риск развития рака молочной железы также был ассоциирован с мутантным аллелем rs2839698 (ОШ = 1,33, 95 % ДИ: 1,03-1,71, Pz = 0,03, Pi2 = 0,05). Значимых ассоциаций с риском развития рака молочной железы полиморфизмов rs2107425, rs217727, rs3741219 не обнаружили. Настоящий метаанализ показал, что полиморфизм rs2839698 H19 ассоциирован с риском развития рака молочной железы.

1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660

2. Yuan Y., Wang Y., Niu X. et al. Association of lncRNA H19 polymorphisms with cancer susceptibility: An updated meta-analysis based on 53 studies. Frontiers in genetics. 2022;(13):1051766. doi: 10.3389/fgene.2022.1051766

3. Taniue K., Akimitsu N.. The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci. 2021;22(2):632. doi: 10.3390/ijms22020632

4. Ghahramani Almanghadim H., Ghorbian S., Khademi N.S. et al. New Insights into the Importance of Long Non-Coding RNAs in Lung Cancer: Future Clinical Approaches. DNA and cell biology. 2021;40(12):1476–1494. doi: 10.1089/dna.2021.0563

5. Kallen A.N., Zhou X.B., Xu J. et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Molecular cell. 2013;52(1):101–112. doi: 10.1016/j.molcel.2013.08.027

6. Yoshimizu T., Miroglio A., Ripoche M.A. et al. The H19 locus acts in vivo as a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(34):2417–12422. doi: 10.1073/pnas.0801540105

7. Zhang L., Yang F., Yuan J.H. et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34(3):577–586. doi: 10.1093/carcin/bgs381

8. Moher D., Shamseer L., Clarke M. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1

9. Barnholtz-Sloan J.S., Shetty P.B., Guan X. et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis. 2010;31(8):1417–1423. doi: 10.1093/carcin/bgq128

10. Butt S., Harlid S., Borgquist S. et al. Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC research notes. 2012;(5):414. URL: https://www.researchgate.net/publication/230621915_Genetic_predisposition_parity_age_at_first_childbirth_and_risk_for_breast_cancer

11. Gong W.J., Yin J.Y., Li X.P. et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37(6):8349–8358. doi: 10.1007/s13277-015-4497-5

12. Xia Z., Yan R., Duan F. et al. Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population. Medicine. 2016;95(7):e2771. doi: 10.1097/MD.0000000000002771

13. Hassanzarei S., Hashemi M., Sattarifard H. et al. Genetic polymorphisms in long noncoding RNA H19 are associated with breast cancer susceptibility in Iranian population. Meta Gene. 2017 Dec;(14):1-5. doi: 10.2147/OTT.S127962

14. Lin Y., Fu F., Chen Y. et al. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. OncoTargets and therapy. 2017;(10):4369–4378. doi: 10.2147/OTT.S127962

15. Cui P., Zhao Y., Chu X. et al. SNP rs2071095 in LincRNA H19 is associated with breast cancer risk. Breast cancer research and treatment. 2018;171(1):161–171. URL: https://link.springer.com/article/10.1007/s10549-018-4814-y

16. Abdollahzadeh S., Ghorbian S. Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer. Journal of clinical laboratory analysis. 2019;33(3):e22826. doi: 10.1002/jcla.22826

17. Safari M.R., Mohammad Rezaei F., Dehghan A. et al. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in Iranian population. Gene. 2019;(701):121–124. doi: 10.1016/j.gene.2019.03.036

18. Li W., Jiang X., Jin X. et al. Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction. Medicine (Baltimore). 2020 Apr;99(15):e19322. doi: 10.1097/MD.0000000000019322

19. Kit O..I, Timofeeva S.V., Sitkovskaya A.O. et al. Biobank of the “National Medical Research Centre for Oncology” as a resource for conducting research in the field of personalized medicine. Modern Oncology. 2022; (24):6-11. doi: 10.26442/18151434.2022.1.201384

20. Chen L., Zhang S. Long noncoding RNAs in cell differentiation and pluripotency. Cell and tissue research. 2016;366(3):509–521. doi: 10.1007/s00441-016-2451-5

21. Gao Y., Liu Y., Du L. et al. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Medical oncology (Northwood, London, England). 2015;32(1):362. doi: 10.1007/s12032-014-0362-4

22. Liu X., Zhao Y., Li Y., Zhang J. Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects. Artificial cells, nanomedicine, and biotechnology. 2020;48(1):15–27. doi: 10.1080/21691401.2019.1699804

23. Vladimirova L.Yu., Storozhakova A.E., Snezhko T.A., et al. Hormone-positive HER2-negative metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46-51. doi: 10.37748/2687-0533-2020-1-2-6